Enzastaurin for Patients With Metastatic Colorectal Cancer

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

28 participants

Study Classification

INTERVENTIONAL

Study Start Date

2005-08-31

Study Completion Date

2008-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Enzastaurin given daily to participants with colorectal cancer who have Stage 4 disease and have not received prior chemotherapy for advanced colorectal cancer

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study of Irinotecan Plus Cetuximab With or Without Enzastaurin in Participants With Colorectal Cancer

NCT00437268

Colorectal Cancer Colorectal Carcinoma Colorectal Tumor

COMPLETED PHASE2

Study of Enzastaurin With 5-Fluorouracil/Leucovorin (5-FU/LV) Plus Bevacizumab as Maintenance Regimen Following First Line Therapy for Metastatic Colon Cancer

NCT00612586

Colorectal Cancer

COMPLETED PHASE2

Eniluracil and Surgery in Treating Patients With Primary or Metastatic Colorectal Cancer

NCT00004195

Colorectal Cancer

COMPLETED PHASE2

Randomized Trial With Dendritic Cells in Patients With Metastatic Colorectal Cancer

NCT01413295

Colorectal Neoplasms

COMPLETED PHASE2

Study of Micrometastases in Patients With Stage I or Stage II Localized Colon Cancer That Can Be Removed by Surgery

NCT01097265

Colorectal Cancer

UNKNOWN PHASE2/PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Colonic Neoplasms

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Enzastaurin HCl

Group Type EXPERIMENTAL

Enzastaurin HCl

Intervention Type DRUG

1200 milligrams (mg) loading dose orally, then 500 mg, orally, daily, up to six 28-day cycles.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Enzastaurin HCl

1200 milligrams (mg) loading dose orally, then 500 mg, orally, daily, up to six 28-day cycles.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

LY317615

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* diagnosed with colorectal cancer that is advanced or metastatic (has spread to other parts of the body); able to visit the doctor's office every 28 days for at least 6 months; able to swallow tablets

Exclusion Criteria

* women cannot be pregnant or breastfeeding; no history of significant heart disease or any other significant medical problems as determined by the participant's physician

Minimum Eligible Age

19 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No